Loading
Myung-Ju Ahn is one of Asia's most prolific lung cancer trialists, a steady presence on the steering committees of the EGFR, ALK, and immunotherapy trials that set today's standards.
Myung-Ju Ahn leads thoracic medical oncology at Samsung Medical Center and has been a principal or co-investigator on many of the pivotal NSCLC trials of the last decade, including osimertinib, lorlatinib, and checkpoint-inhibitor studies with large Korean enrolment. Her work spans EGFR resistance, ALK inhibitors, and head-and-neck immunotherapy.
| Title | Journal | Year |
|---|---|---|
| Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer (FLAURA) | NEJM | 2018 |
| Lorlatinib versus crizotinib in advanced ALK-positive NSCLC (CROWN) | NEJM | 2020 |
| DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer | New England Journal of Medicine | 2023 |
Shares ALK-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag lung.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag lung.
Shares Non-small-cell lung cancer and the tag lung.
Shares Non-small-cell lung cancer and the tag lung.
Shares Non-small-cell lung cancer and the tag lung.
Shares Non-small-cell lung cancer and the tag lung.
Shares Non-small-cell lung cancer and the tag lung.
Shares Non-small-cell lung cancer and the tag lung.